How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013

(2015) Ylenia Ingrasciotta et al.   BIODRUGS

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

(2015) Pere Gascón et al.   SUPPORTIVE CARE IN CANCER

Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

(2014) Paola M. Cutroneo et al.   DRUG SAFETY

Traceability of biologicals: present challenges in pharmacovigilance

(2014) Niels S Vermeer et al.   Expert Opinion On Drug Safety

Biosimilars: what clinicians should know

(2012) M. Weise et al.   BLOOD

Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

(2011) Matti Aapro et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE